However, in end-stage renal disease and in nondialysis chronic kidney disease patients, treatment with EPO or ESA (erythropoiesis stimulating agents) showed inadequate efficacy and cardiovascular toxicity in terms of risk of cardiovascular hospitalization or stroke (11). Here, EPO is linked to chronic kidney disease.